EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Malondialdehyde (MDA) in the Temporal Progression of Chronic Spinal Cord Injury

Sergio Haro Girón iD, Jorge Monserrat Sanz iD, Miguel A Ortega iD, Cielo Garcia-Montero iD, Oscar Fraile-Martínez iD, Ana M Gómez-Lahoz, Diego Liviu Boaru, Diego de Leon-Oliva, Luis G Guijarro, Mar Atienza-Perez, David Diaz, Elisa Lopez-Dolado und 1 weitere

Journal of Personalized Medicine · 02.04.2023 · 13 (4) · 626

DOI: 10.3390/jpm13040626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 02.04.2023. Verfasst von Sergio Haro Girón und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comunidad de Madrid, Fondo de Investigación de la Seguridad Social (Spain), Spanish Ministerio de Ciencia y Tecnología, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oxidative stress is a major signature of spinal cord injury (SCI). The altered levels of various oxidative stress markers have been demonstrated in acute and chronic SCI. However, the variation of these markers in patients with chronic SCI depending on the time since the initial injury has not been explored yet.

Objective

Our aim was to measure plasma levels of malondialdehyde (MDA), a marker of lipid peroxidation in patients with SCI stratified in different periods of suffering the injury (0–5 years, 5–10 years, and more than 10 years). Patients and methods: This cross-sectional study enrolled patients with SCI (N = 105) from different periods of the lesion and healthy control (HC) subjects (N = 38): short period (SCI SP, N = 31, time of evolution less than 5 years); early chronic (SCI ECP, N = 32, time of evolution 5–15 years); and late chronic (SCI LCP, N = 42, time of evolution more than 15 years). The plasma levels of MDA were measured using a commercially available colorimetric assay.

Results

Patients with SCI had significantly higher plasma levels of MDA than HC subjects. Receiver operating characteristic (ROC) curve analysis for plasma MDA levels in patients with SCI demonstrated areas under the curve (AUC) of 1 (HC vs. SCI-SP); 0.998 (HC vs. SCI-ECP); and 0.964 (HC vs. SCI-LCP). Additionally, three ROC curves were used to compare the different concentrations of MDA between the subgroups of patients with SCI, and the resulting AUCs were: 0.896 (SCI-SP vs. SCI-ECP); 0.840 (SCI-ECP vs. SCI-LCP); and 0.979 (SCI-SP vs. SCI-LCP).

Conclusion

Plasma concentration of MDA can be considered as an oxidative stress biomarker to assess the prognosis of SCI in chronic stages.

Schlagwörter

Stichwörter der Autor:innen

lipid peroxidationmalondialdehyde (MDA)oxidative stressplasma biomarkerprognosisspinal cord injury (SCI)

Autor:innen und Institutionen

  • Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
  • Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
  • Unit of Biochemistry and Molecular Biology, Department of System Biology (CIBEREHD), University of Alcalá, 28801 Alcala de Henares, Spain.
  • Service of Rehabilitation, National Hospital for Paraplegic Patients, Carr. de la Peraleda, S/N, 45004 Toledo, Spain.
  • Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain.

ORCID-Profile: Sergio Haro Girón, Jorge Monserrat Sanz, Miguel A Ortega, Cielo Garcia-Montero, Oscar Fraile-Martínez, Melchor Álvarez-Mon

Förderung

  • Comunidad de Madrid
  • Fondo de Investigación de la Seguridad Social (Spain)
  • Spanish Ministerio de Ciencia y Tecnología, Instituto de Salud Carlos III
  • Spanish Ministerio de Economía y Competitividad
  • ProACapital, Halekulani S.L.

Zitieren

APA

Haro Girón, S., Monserrat Sanz, J., Ortega, M. A., Garcia-Montero, C., Fraile-Martínez, O., Gómez-Lahoz, A. M., Boaru, D. L., de Leon-Oliva, D., Guijarro, L. G., Atienza-Perez, M., Diaz, D., Lopez-Dolado, E., & Álvarez-Mon, M. (2023). Prognostic Value of Malondialdehyde (MDA) in the Temporal Progression of Chronic Spinal Cord Injury. Journal of Personalized Medicine, 13(4), 626. https://doi.org/10.3390/jpm13040626

Vancouver

Haro Girón S, Monserrat Sanz J, Ortega MA, Garcia-Montero C, Fraile-Martínez O, Gómez-Lahoz AM, et al. Prognostic Value of Malondialdehyde (MDA) in the Temporal Progression of Chronic Spinal Cord Injury. Journal of Personalized Medicine. 2023;13(4):626. doi:10.3390/jpm13040626

BibTeX
@article{HaroGirn2023,
  author = {Haro Girón, Sergio and Monserrat Sanz, Jorge and Ortega, Miguel A and Garcia-Montero, Cielo and Fraile-Martínez, Oscar and Gómez-Lahoz, Ana M and Boaru, Diego Liviu and de Leon-Oliva, Diego and Guijarro, Luis G and Atienza-Perez, Mar and Diaz, David and Lopez-Dolado, Elisa and Álvarez-Mon, Melchor},
  title = {Prognostic Value of Malondialdehyde (MDA) in the Temporal Progression of Chronic Spinal Cord Injury},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {4},
  pages = {626},
  doi = {10.3390/jpm13040626}
}
Kostenlos starten →